RxDoctor Payments DataLook up a doctor →

Benjamin Kalsmith, MD

Cardiovascular Disease · Pgh, PANPI 1902925837

Payments from drug & device makers

$1,661,400in general payments, 2019–2025

Across 2,987 payments — averaging $556.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$310K
  • Lilly USA, LLC$262K
  • Novo Nordisk$218K
  • Boehringer Ingelheim$188K
  • Amgen$172K
  • Pfizer$126K
  • plus $385K from 47 others

What the payments were for

  • Consulting fees$42,6973%
  • Speaking & faculty fees$1,497,50490%
  • Grants$80%
  • Travel & lodging$64,0944%
  • Food & beverage$56,9733%
  • Education$1240%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,661,400 in reported general payments places this provider in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$312,484
Medicare patients
1,062
Services billed
3,886

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,627$1,688,001
EntrestoSacubitril/Valsartan412$489,505
JardianceEmpagliflozin317$319,123
Repatha SureclickEvolocumab505$300,265
VyndamaxTafamidis13$296,122
VyndaqelTafamidis Meglumine12$273,344
XareltoRivaroxaban124$124,424
BrilintaTicagrelor82$67,750
OzempicSemaglutide52$56,787
FarxigaDapagliflozin Propanediol38$52,537
TrulicityDulaglutide27$34,617
MultaqDronedarone Hcl24$29,304
WegovySemaglutide22$28,679
Praluent PenAlirocumab45$28,288
VerquvoVericiguat20$23,595

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndamax, Vyndaqel$126,180$2,257,4661,652 claims
NovartisEntresto$30,234$489,505412 claims
Boehringer IngelheimJardiance, Tradjenta$187,998$325,320329 claims
Johnson & JohnsonXarelto$1,405$124,424124 claims
AstraZenecaBrilinta, Farxiga$75,181$120,288120 claims
Novo NordiskOzempic, Wegovy$218,321$85,46674 claims
Lilly USA, LLCTrulicity$261,541$34,61727 claims
Sanofi-aventis U.S. LLCMultaq$8,408$29,30424 claims
MerckVerquvo$965$23,59520 claims
Esperion Therapeutics, Inc.Nexlizet$62,823$10,57819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Pgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →